HIV gp120 vaccine - Merck/RepligenAlternative Names: RP 135; RP 400c
Latest Information Update: 12 Jan 2000
At a glance
- Originator Repligen
- Developer Merck & Co; Repligen
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 12 Jan 2000 New profile, split from generic HIV gp120 vaccine profile